insights_auto
Sebab BT3 meningkat 2.14%?
Terokai Dengan Lebih Terperincichevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
€0.76
arrow_upward
+2.14%(+0.016) 1H
20 Nov, 10:00:00 PTG GMT+1 · EUR
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk BT3...
Buka
€0.76
Tinggi
€0.76
Rendah
€0.76
Permodalan Pasaran
195.26J
Purata volum
100.00
Volum
0.00
tgi 52 mgu
€1.68
rdh 52 mgu
€0.72
Bilangan pekerja
75
Buka
€0.76
Tinggi
€0.76
Rendah
€0.76
Permodalan Pasaran
195.26J
Purata volum
100.00
Volum
0.00
tgi 52 mgu
€1.68
rdh 52 mgu
€0.72
Bilangan pekerja
75
Cerita berita
Daripada sumber web dan rakan kongsi berita
Blockonomi
·
1 jam lalu
S&P 500 Correction Deepens as Investors Watch for Signs of a Market Bottom
The Motley Fool
·
6 jam lalu
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
Beinsure
·
20 jam lalu
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
JournalArta
·
18 minit lalu
S&P 500 Valuation Hits Rare Level for Fifth Time This Century
Profil
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Perihal Lineage Cell Therapeutics Inc